Novel Microfluidic Platform for Cancer Research
AMSBIO, a transatlantic life sciences company, and the University of Strathclyde (Glasgow, UK) have pioneered a multidisciplinary approach combining expertise in microfluidics and 3D culture to develop a novel microfluidic platform for cancer research. The new platform combines microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids to enable formation and long-term culture of 3D multicellular tumors / organoids for drug screening and...
Related Biotechnology, Pharmaceutical and Healthcare News
Original Article: Novel Microfluidic Platform for Cancer Research
NEXT ARTICLE
More From BioPortfolio on "Novel Microfluidic Platform for Cancer Research"
